CervoMed to Participate in H.C. Wainwright 3rd Annual BioConnect Investor Conference

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

CervoMed Inc. (NASDAQ: CRVO), a clinical stage company specializing in treatments for age-related neurologic disorders, has announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference. The event will take place in New York on May 20, 2025.

Company management will engage in a fireside chat scheduled from 5:00 to 5:30 PM ET and will also conduct one-on-one investor meetings. The fireside chat will be available via webcast through the company's website and a dedicated event platform.

News Market Reaction

-5.01%

1 alert

-5.01% News Effect

On the day this news was published, CRVO declined 5.01%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

05/07/2025 - 08:00 AM

BOSTON, May 07, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Company management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 3^rd Annual BioConnect Investor Conference being held in New York, NY, on Tuesday, May 20, 2025.

Presentation Details
Format: Fireside Chat
Date: Tuesday, May 20, 2025
Time: 5:00 – 5:30 PM ET
Webcast Link: https://journey.ct.events/view/ff005743-cd3c-4c4c-bd4d-ba8d0c84c859

The webcast of the fireside chat will be accessible in the Investor section of the CervoMed website https://www.cervomed.com/.

About CervoMed
CervoMed is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause clinical disease expression in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with DLB.

Investor Contact:
PJ Kelleher
LifeSci Advisors
Investors@cervomed.com
617-430-7579

FAQ

When is CervoMed (CRVO) presenting at the H.C. Wainwright BioConnect Conference 2025?

CervoMed (CRVO) will present at the H.C. Wainwright BioConnect Conference on Tuesday, May 20, 2025, from 5:00 to 5:30 PM ET in New York.

What type of company is CervoMed (CRVO)?

CervoMed (CRVO) is a clinical stage company that focuses on developing treatments for age-related neurologic disorders.

How can investors access CervoMed's (CRVO) presentation at the H.C. Wainwright conference?

Investors can access the fireside chat webcast through CervoMed's website (www.cervomed.com) in the Investor section or via the dedicated event platform link.